Philip L. McCarthy, MD

Professor of Oncology
Director, Blood and Marrow Transplant Program
Roswell Park Cancer Institute
Buffalo, New York
Last modified: January 31, 2020
Authored Items
Effects of cytokine-release syndrome: CNS toxicity and impact on CAR T cells
Philip L. McCarthy, MD
FAQ Library published on May 8, 2019
What is cytokine-release syndrome and how is it treated?
Philip L. McCarthy, MD
FAQ Library published on April 24, 2019
What are the current recommendations for providing a herpes zoster vaccine to patients with multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on September 10, 2018
Is there a benefit to providing antibiotic prophylaxis to patients being treated for multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on July 16, 2018
What is the current standard of care for follow-up monitoring of patients diagnosed with smoldering multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on June 4, 2018
What are the criteria for high-risk progression?
Philip L. McCarthy, MD
FAQ Library published on August 9, 2017
Update on the CALGB-100104 (Alliance) randomized trial
Philip L. McCarthy, MD
Clinical Pearls Podcasts published on July 24, 2017
When is a patient transplant eligible?
Philip L. McCarthy, MD
FAQ Library published on June 28, 2017
What is the New R-ISS for Multiple Myeloma and Should I Be Using it?
Philip L. McCarthy, MD
FAQ Library published on November 25, 2015
How long should my patients be on maintenance therapy?
Philip L. McCarthy, MD
FAQ Library published on September 9, 2015
What are the essential considerations in a survivorship plan for multiple myeloma?
Philip L. McCarthy, MD
FAQ Library published on August 26, 2015
Why is the FIRST study important to practice?
Philip L. McCarthy, MD
FAQ Library published on November 6, 2013 in Clinical Trials

MediCom Worldwide, Inc. Links